Skip to content
Evigrade
CriticalSelective mineralocorticoid receptor antagonist×Potassium-sparing diuretic, collecting duct sodium channel blocker

Updated · Methodology

Mechanism

Eplerenone prevents aldosterone from binding to its receptor and can therefore raise blood potassium (eplerenone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Triamterene blocks sodium channels in the distal tubule of the kidney, so the kidneys excrete more sodium and less potassium (furosemide/triamterene SmPC, AEMPS). Triamterene conserves potassium through a direct effect on the renal tubule, and this action is not directly related to aldosterone secretion or antagonism (triamterene label, US Food and Drug Administration, FDA). Patients receiving eplerenone with another potassium-sparing diuretic have a higher risk of hyperkalaemia. Potassium-sparing diuretics also add to the effect of other diuretics and of blood pressure medicines (eplerenone SmPC, AEMPS).

Symptoms

Serum potassium can rise to 5.5 mEq/L or higher with any potassium-sparing agent, more often in people with impaired kidney function or diabetes, in older people and in the severely ill. Uncorrected hyperkalaemia may be fatal (triamterene label, US Food and Drug Administration, FDA). Rarely, hyperkalaemia with triamterene has been associated with heart rhythm disturbances. Two deaths have been reported in patients who received triamterene together with spironolactone, another potassium-sparing drug, although in one case the recommended dose was exceeded and in the other electrolytes were not properly monitored (FDA). The US eplerenone label lists warning signs to watch for: dizziness, diarrhoea, vomiting, a fast or irregular heartbeat, swelling of the legs and difficulty breathing (eplerenone label, FDA). During eplerenone treatment, the risk of hyperkalaemia is higher in older people and in kidney or liver impairment (eplerenone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).

Management

The combination is contraindicated. The Spanish eplerenone summary of product characteristics (SmPC) contraindicates eplerenone in patients receiving potassium-sparing diuretics. According to its own documents, triamterene belongs to this class (eplerenone and furosemide/triamterene SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS; triamterene label, US Food and Drug Administration, FDA). The US eplerenone label names triamterene, but its contraindication applies only to the treatment of hypertension, which is not an approved indication for eplerenone in Spain (eplerenone label, FDA; eplerenone SmPC, AEMPS). The US triamterene label says triamterene must not be given to patients receiving other potassium-sparing agents, such as spironolactone or amiloride (FDA). In the Spanish register, triamterene is available only in combination with furosemide, and the SmPC of this combination warns that triamterene with potassium-sparing diuretics or potassium supplements increases the risk of both low and high potassium (AEMPS). During eplerenone treatment, measure potassium before starting, within the first week and one month after starting or changing the dose, and periodically thereafter. If potassium reaches 6.0 mmol/L or higher, withhold eplerenone (eplerenone SmPC, AEMPS). If potassium rises during triamterene treatment, obtain an electrocardiogram (ECG) and stop triamterene. A widened QRS complex or arrhythmia requires prompt additional treatment (FDA). After intensive or prolonged treatment, withdraw triamterene gradually, because, in theory, a rebound loss of potassium could occur after abrupt withdrawal (FDA).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Eplerenone

Other interactions with Triamterene